Real-world effectiveness of CDK4/6i in first-line treatment of HR+/HER2− advanced/metastatic breast cancer: updated systematic review

AimSince 2021, additional real-world evidence (RWE) has emerged on the effectiveness of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) as first-line treatment of HR-positive/HER2-negative (HR+/HER2−) advanced/metastatic breast cancer (A/MBC), necessitating this updated review.MethodsMEDLINE®, Emba...

Descrición completa

Detalles Bibliográficos

Principais autores:	Nadia Harbeck, Adam Brufsky, Chloe Grace Rose, Beata Korytowsky, Connie Chen, Krista Tantakoun, Endri Jazexhi, Do Hoang Vien Nguyen, Meaghan Bartlett, Imtiaz A. Samjoo, Timothy Pluard
Formato:	Artigo
Idioma:	Inglês
Publicado:	Frontiers Media S.A. 2025-03-01
Series:	Frontiers in Oncology
Assuntos:	CDK4/6 inhibitors quality assessment breast metastasis real-world evidence systematic literature review
Acceso en liña:	https://www.frontiersin.org/articles/10.3389/fonc.2025.1530391/full
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!